BYON4413 vs CD123 targeted CAR-NK cells
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD123 · full Acute Myeloid Leukemia pipeline
BYON4413
Developed by Byondis B.V.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
CD123 targeted CAR-NK cells
Developed by Chongqing Precision Biotech Co., Ltd
NCT06006403 · Phase 1/2 · completed
This was a non-randomized, open-label study with no comparator and only five participants. Its primary outcomes included safety and objective response rate, but results are not posted, so whether the primary outcomes were met cannot be determined.
Next expected readout: June 2027 · NCT06690827 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Acute Myeloid Leukemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | BYON4413 | CD123 targeted CAR-NK cells |
|---|---|---|
| OS, median | —Not reported | —Not reported |
| Complete remission | —Not reported | —Not reported |
| Event-free survival, median | —Not reported | —Not reported |
| Duration of response, median | —Not reported | —Not reported |
OS, median
- BYON4413
- —Not reported
- CD123 targeted CAR-NK cells
- —Not reported
Complete remission
- BYON4413
- —Not reported
- CD123 targeted CAR-NK cells
- —Not reported
Event-free survival, median
- BYON4413
- —Not reported
- CD123 targeted CAR-NK cells
- —Not reported
Duration of response, median
- BYON4413
- —Not reported
- CD123 targeted CAR-NK cells
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
BYON4413: no structured comparison results are available for Acute Myeloid Leukemia.
CD123 targeted CAR-NK cells: no structured comparison results are available for Acute Myeloid Leukemia.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BYON4413's landscape · CD123 targeted CAR-NK cells's landscape